Page 218 - Haematologica May 2020

F. Schieppati et al.
and is highly associated with overall survival
in B cell lymphoma patients. Br J Haematol.
2014;166(3):369–374.
26. Petrich AM, Gandhi M, Jovanvoic B, et al.
Impact of induction regimen and stem cell transplantation on outcomes in patients with double-hit lymphoma : a large multi- center retrospective analysis. Blood. 2014;124(15):1-9.
27. Quesada A, Medeiros L, Desai P, et al. Increased MYC copy number is an inde- pendent prognostic factor in patients with diffuse large B-cell lymphoma. Mod Pathol. 2017;30(12):1688-1697.
28. Testoni M, Kwee I, Greiner TC, et al. Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP. Br J Haematol. 2011;155(2):274- 277.
29. Landsburg DJ, Falkiewicz MK, Petrich AM, et al. Sole rearrangement but not amplifica-
tion of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable. Br J Haematol. 2016;175(4): 631-640.
30. Testoni M, Zucca E, Young KH, Bertoni F. Genetic lesions in diffuse large B-cell lym- phomas. Ann Oncol. 2015;26(6):1069-1080.
31. Pophali P, Marinelli LM, Ketterling RP, et al. High Level MYC Amplification in Aggressive B-Cell Lymphomas: Is It a Marker of Aggressive Disease? Blood. 2018;132(Suppl 1):1693.
32. Valentino C, Kendrick S, Johnson N, et al. Colorimetric In Situ Hybridization Identifies MYC Gene Signal Clusters Correlating With Increased Copy Number, mRNA, and Protein in Diffuse Large B-cell Lymphoma Carlo. Am J Clin Pathol. 2013;139(2):242- 254.
33. Swerdlow SH. Diagnosis of ‘double hit’ dif-
fuse large B-cell lymphoma and B-cell lym- phoma, unclassifiable, with features inter- mediate between DLBCL and Burkitt lym- phoma: when and how, FISH versus IHC. Hematol Am Soc Hematol Educ Program. 2014;2014(1):90-99.
34. Friedberg JW. How I Treat How I treat dou- ble-hit lymphoma. Blood. 2017;130(5):590- 597.
35. Sun H, Savage K, Karsan A, et al. Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX- M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2015;15(6):341-348.
36. Oki Y, Noorani M, Lin P, et al. Double hit lymphoma : the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014;166:891-901.
1378
haematologica | 2020; 105(5)